# Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings and a Potential 12% Upside for This Medical Device Innovator

- Link: https://www.directorstalkinterviews.com/glaukos-corporation-gkos-stock-analysis-strong-buy-ratings-and-a-potential-12-upside-for-this-medical-device-innovator/4121241183
- Published: 2026-02-23T11:27:46+00:00
- Author: Madison Wilson

Investors eyeing the healthcare sector might want to take a closer look at Glaukos
Corporation (NYSE: GKOS), a leader in ophthalmic pharmaceuticals and medical technology.
With a market capitalization of $6.91 billion, Glaukos has carved a niche in treating
glaucoma, corneal disorders, and retinal diseases with innovative solutions like
the iStent micro-bypass stents. As the company continues to expand its product offerings
and market reach, it presents a compelling opportunity for growth-oriented investors.

Glaukos’ current stock price stands at $120.27, with a modest price change of 0.03%.
Over the past 52 weeks, the stock has seen fluctuations between $74.67 and $125.90,
indicating a robust recovery in its market valuation. The stock’s recent performance
is bolstered by a strong 50-day moving average of $114.76, significantly above its
200-day moving average of $97.79, suggesting a positive momentum.

While Glaukos’ trailing P/E ratio remains unavailable, the forward P/E ratio reaches
a lofty 277.10, reflecting high investor expectations about the company’s future
earnings potential. Despite the absence of key valuation metrics like the PEG ratio
and price/book, the company’s impressive revenue growth of 35.70% is a testament
to its expanding market footprint and successful product innovations.

However, not all performance metrics paint a rosy picture. The company reported 
an EPS of -1.54 and a return on equity of -26.38%, indicating areas where operational
efficiencies could be enhanced. The absence of a dividend may deter income-focused
investors, but the zero payout ratio suggests that Glaukos is reinvesting its earnings
back into the business, potentially paving the way for future growth.

Analyst sentiment towards GKOS is overwhelmingly positive, with 13 buy ratings and
a single sell rating. The average target price of $134.79 implies a potential upside
of 12.07%, positioning Glaukos as an attractive prospect for investors seeking capital
appreciation. The target price range extends from $72.00 to $165.00, indicating 
diverse opinions on its valuation, yet the consensus leans towards growth.

Technically, the stock’s RSI of 31.01 indicates that it is approaching oversold 
territory, which could present a buying opportunity for contrarian investors. The
MACD value of 0.11, with a signal line at -0.19, suggests a bullish trend that might
appeal to momentum investors.

Glaukos continues to innovate with products like the iDose TR, iAccess, and retinal
XR platform, targeting a range of eye disorders. These advancements not only expand
its treatment portfolio but also strengthen its position in the competitive medical
device industry.

For investors seeking exposure in the healthcare sector, particularly in medical
technology, Glaukos Corporation offers an intriguing blend of growth potential and
innovative drive. While the high forward P/E ratio and recent net losses warrant
caution, its strong buy ratings and product pipeline hold promise for future value
creation. As Glaukos advances its mission to transform ophthalmic care, it remains
a stock to watch closely.

Share on: